Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 310

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 310
---
 several sources including existing cash balances, future cash flows from operations
and the proceeds from equity offerings, we cannot assure you that any of these funding sources will be available to us on favorable terms,
or at all. Further, even if we can raise funds from all of the above sources, the amounts raised may not be sufficient to meet our future
capital requirements.

Operating
results may vary significantly in future periods.

Our
expenses and operating results have fluctuated in the past and our revenues, expenses, and operating results are likely to fluctuate
significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to:

    ●
    commercial
    sales of our products;

    ●
    our
    achievement of product development objectives and milestones;

    ●
    clinical
    trial enrollment and expenses;

    ●
    research
    and development expenses; and

    ●
    the
    timing and nature of contract manufacturing and contract research payments.

A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter. Because of these factors, our financial results
in one or more future quarters may fail to meet the expectations of securities analysts or our stockholders, which could cause our share
price to decline.

29

We
depend upon our key personnel and our ability to attract and retain employees.

Our
future growth and success depend on our ability to recruit, retain, manage, and motivate our employees. The inability to hire or retain
experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Due
to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific,
technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense
competition, we may be unable to continue to attract and retain the qualified personnel necessary for the development of our business
or to recruit suitable replacement personnel.

Our
proprietary information, or that of our customers, suppliers, and business partners, may be lost or we may suffer security breaches.

In
the ordinary course of our business, we will collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our customers, suppliers and business partners, and personally
identifiable information of our customers,